News

Insulin Degludec's Long Duration Sways FDA Panel

Publish date: November 8, 2012

 

AT A MEETING OF THE FOOD AND DRUG ADMINISTRATION ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE

The company also has submitted an application for approval of IDeg and IDegAsp in Europe, in Canada, and other countries. They were approved in Japan in late September.

UPDATED 11/12/12

Pages

Recommended Reading

HbA1c Declines Cut 5-Year Death Rate
MDedge Cardiology
Hepatic Concerns Influence Panel's Vote on ApoB Inhibitor
MDedge Cardiology
Glucose Excursions Linked to Ventricular Tachycardia
MDedge Cardiology
MI Rate Declines After Smoke-Free Laws Enacted in Olmsted County
MDedge Cardiology
Weight Gain Following Diabetes Diagnosis Boosts Mortality
MDedge Cardiology
Diabetes Deaths Decline in Tots and Teens
MDedge Cardiology
FREEDOM: CABG Shows Excellent Cost Effectiveness
MDedge Cardiology
AMG145 Delivers Robust Results for Statin-Intolerant Patients
MDedge Cardiology
Practice Changer: CABG Bests Multivessel Stenting in Diabetes
MDedge Cardiology
Aliskiren Didn't Protect Heart, Kidneys in Diabetes
MDedge Cardiology